Premium
Spin trapping agent phenyl N‐tert‐ butylnitrone protects against the onset of drug‐induced insulin‐dependent diabetes mellitus
Author(s) -
Tabatabaie Tahereh,
Kotake Yashige,
Wallis Gemma,
Jacob Jane M,
Floyd Robert A
Publication year - 1997
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(97)00327-x
Subject(s) - streptozotocin , diabetes mellitus , insulin , pancreas , medicine , nitric oxide , in vivo , endocrinology , captopril , pharmacology , glycated hemoglobin , chemistry , type 2 diabetes , biology , microbiology and biotechnology , blood pressure
Insulin‐dependent diabetes mellitus is an autoimmune disease believed to be caused by an inflammatory process in the pancreas leading to selective destruction of the β‐cells. Cytokines and nitric oxide (NO) have been shown to be involved in this destruction. Phenyl N ‐ tert ‐butylnitrone (PBN) has demonstrated protective effects against several pathological conditions including ischemia‐reperfusion injury and endotoxin‐induced shock. We report here that PBN co‐administration can prevent the onset of the STZ‐induced diabetes in mice. PBN co‐treatment inhibited the streptozotocin (STZ)‐induced hyperglycemia, the elevation in the level of glycated hemoglobin and weight loss in the treated mice. Histological observations indicated destruction of β‐cells in the STZ‐treated animals and its prevention by PBN co‐treatment. EPR spin trapping experiments in the pancreas indicated the in vivo formation of NO in STZ‐treated animals and its attenuation by PBN treatment.